GENE ONLINE|News &
Opinion
Blog

2022-05-24| Special

Convergence, Communication and Commercialization, The Cornerstones In Emerging Regulatory Trends

by Arvind C. Shekhar
Share To
photo credit to ASCGT

At the recently concluded 25th annual meeting of the American Society for Gene and Cell Therapy (ASGCT), Dr. Peter Marks, Director, Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration and Dr. Ana Hidalgo-Simon, Head of Advanced Therapies, European Medicines Agency took part in a Fireside chat titled “State of the Field: Emerging Regulatory Trends”. The session was aimed at creating greater awareness about how the two main regulatory agencies (USFDA and EMA) are gearing to regulate the field of cell and gene therapy. In the freewheeling conversation the speakers shared their insights on various aspects ranging from importance of public-private partnerships, lessons learned from COVID-19 to the role of innovative trial design and primary biomarkers in accelerated development of gene therapies. 

 

Role of Public-Private Partnerships In Cell And Gene Therapies

 

GO Prime with only $1.49 now

LATEST
Neomorph Links Together With Novo Nordisk in a $1.46 Billion Molecular Glue Partnership Deal
2024-02-27
Breakthrough Study Shows Anti-IgE Antibody Safeguards Children with Multiple Food Allergies
2024-02-27
Cortisol: New Discoveries on its Impact Across Health, Culture, and Evolution
2024-02-26
Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
2024-02-23
Revolutionary AI-Powered Respiratory Monitor Maker Gets Financial Boost with Latest Funding
2024-02-21
Researchers Predict Drug Interactions with Machine Learning to Enhance Patient Safety
2024-02-21
USC-Led Study Reveals Benefits of Fasting-Mimicking Diet in Reducing Disease Risk and Slowing Aging
2024-02-21
EVENT
Scroll to Top